Conv. Plasma
Nigella Sativa
Peg.. Lambda

All HCQ studies
Meta analysis
Home COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Prolonged viral shedding.. 65% Improvement Relative Risk HCQ for COVID-19  Hong et al.  EARLY TREATMENT Is early treatment with HCQ beneficial for COVID-19? Retrospective 90 patients in South Korea Improved viral clearance with HCQ (p=0.001) Hong et al., Infect. Chemother., 2020, Jul 2020 Favors HCQ Favors control

Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication

Hong et al., Infect. Chemother., 2020, doi:10.3947/ic.2020.52.e43
Jul 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ 1-4 days from diagnosis was the only protective factor against prolonged viral shedding found, OR 0.111, p=0.001. 57.1% viral clearance with 1-4 days delay vs. 22.9% for 5+ days delayed treatment. Authors report that early administration of HCQ significantly ameliorates inflammatory cytokine secretion and that COVID-19 patients should be administrated HCQ as soon as possible. 42 patients with HCQ 1-4 days from diagnosis, 48 with HCQ 5+ days from diagnosis.
risk of prolonged viral shedding, early vs. late HCQ, 64.9% lower, RR 0.35, p = 0.001, treatment 42, control 48, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hong et al., 16 Jul 2020, retrospective, South Korea, peer-reviewed, 7 authors, dosage not specified.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication
Kyung Soo Hong, Jong Geol Jang, Jian Hur, Jong Ho Lee, PhD Hong Nam Kim, PhD Wonhwa Lee, June Hong Ahn
Infection & Chemotherapy, doi:10.3947/ic.2020.52.3.396
There are no proven therapeutics for Coronavirus disease 2019 (COVID-19) pneumonia outbreak. We observed and analyzed the clinical efficacy of the most used hydroxychloroquine (HCQ) for 30 days. In this study, administration of HCQ <5 days from diagnosis (odds ratio: 0.111, 95% confidence interval: 0.034 -0.367, P = 0.001) was the only protective factor for prolonging of viral shedding in COVID-19 patients. Early administration of HCQ significantly ameliorates inflammatory cytokine secretion by eradicating COVID-19, at discharge. Our findings suggest that patients confirmed of COVID-19 infection should be administrated HCQ as soon as possible.
Ards Definition, Force, Ranieri, Rubenfeld, Thompson et al., Acute respiratory distress syndrome: the Berlin Definition, JAMA
Boulware, Pullen, Bangdiwala, Pastick, Lofgren et al., A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19, N Engl J Med
Du, Yu, Li, Li, Qin et al., Duration for carrying SARS-CoV-2 in COVID-19 patients, J Infect, doi:10.1016/j.jinf.2020.03.053
Hong, Lee, Kim, Huh, Lee et al., Guidelines for laboratory diagnosis of coronavirus disease 2019 (COVID-19) in Korea, Ann Lab Med, doi:10.3343/alm.2020.40.5.351
Liu, Yan, Wan, Xiang, Le et al., Viral dynamics in mild and severe cases of COVID-19, Lancet Infect Dis, doi:10.1016/S1473-3099(20)30232-2
Mehta, Mcauley, Brown, Sanchez, Tattersall et al., HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet, doi:10.1016/S0140-6736(20)30628-0
Pubmed | Crossref, None, doi:10.1001/jama.2016.0287
Pubmed | Crossref, None, doi:10.1093/cid/ciaa351
Pubmed | Crossref, None, doi:10.1093/cid/ciaa451
Singer, Deutschman, Seymour, Shankar-Hari, Annane et al., The third international consensus definitions for sepsis and septic shock (Sepsis-3), JAMA
Smith, Prytherch, Meredith, Schmidt, Featherstone, The ability of the National Early Warning Score (NEWS) to discriminate patients at risk of early cardiac arrest, unanticipated intensive care unit admission, and death, Resuscitation, doi:10.1016/j.resuscitation.2012.12.016
Xu, Chen, Yuan, Yi, Ding et al., Factors associated with prolonged viral RNA shedding in patients with COVID-19, Clin Infect Dis
Zhou, She, Wang, Ma, The duration of viral shedding of discharged patients with severe COVID-19, Clin Infect Dis
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop